> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Priority Voucher Awarded to Leadiant Bioscience
- URL: https://www.fdaweb.com/priority-voucher-awarded-to-leadiant-bioscience/
- Published: 2018-10-25T12:00:00.000Z
- Updated: 2026-09-15T00:40:31.000Z
- Author: David McFarland
- Tags: FDA Policy/General, #legacy-id-D5142676

*Federal Register* notice: FDA has awarded a priority review voucher to Leadiant Bioscience after determining that rare disease drug Revcovi (elapegademase-lvlr) injection meets the award criteria. The product is approved for treating adenosine deaminase-severe combined immunodeficiency in pediatric and adult patients. To view the notice, click [here](https://www.gpo.gov/fdsys/pkg/FR-2018-10-25/pdf/2018-23308.pdf?ref=fdaweb.com).